Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

CID-103 is an anti-CD38 antibody with the potential to be a best-in-class treatment for a myriad of autoimmune diseases as well as antibody mediated rejection (AMR). We are encouraged by our ...

Company Announcement <li /> Johnson & Johnson has decided that it will not exercise its option to receive a ...

and an anti-CD38 antibody, said J&J. It joins a number of other BCMA-directed therapies for multiple myeloma, including GSK's first-to-market antibody-drug conjugate Blenrep (belantamab mafodotin ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

of intravenous HexaBody-CD38 versus subcutaneous daratumumab in patients with anti-CD38 antibody- naïve relapsed or refractory multiple myeloma. Preliminary data submitted by Genmab to J&J ...